Skip to content
DataLookout
Menu

NCT07462377

A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC

StatusRecruiting
PhasePhase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 8 versions: 8 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 6 → 12 locations
  2. Notable Eligibility criteria expanded, about 8 words
    • Study sites: 6 to 8
    • Secondary endpoints: details revised at 4 of 6 entries
    • Study description revised
  3. Minor Study sites revised (6)v6
  4. Minor Site details revised at 1 of 6 sitesv5
  5. Minor Start date changed from estimate of Apr 2026 to Mar 31, 2026
    • Site details revised at 1 of 6 sites
    v4
Show 2 earlier versionsHide 2 earlier versions
  1. Minor Study sites: 5 to 6v3
  2. Notable Trial status: Not Yet Recruiting to Recruiting
    • Site details revised at 5 of 5 sites
    v2
  1. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Evaluation of the safety and tolerability of EPI-326
Timeframe: Up to 3 years.
Determination of the recommended dose and schedule for EPI-326 administration
Timeframe: Up to 3 years.

Secondary (6)

Determination of maximum (Cmax) and minimum (Cmin) plasma concentration
Determination of area under the concentration-time curve (AUC)
Determination of clearance (CL) from the blood
Determination of volume of distribution (Vd)
Objective response rate (ORR)
Show 1 moreShow less
Duration of response (DOR)

Arms and interventions

EPI-326Experimental

Experimental: Dose Escalation

Drugs: EPI-326

Sites

12 sites in 3 countries

United States 6, South Korea 4, Taiwan 2